NCT02950766 — NeoVax neoantigen vaccine trial
NeoVax Plus Ipilimumab in Renal Cell Carcinoma
Registry record
| Registry ID | NCT02950766 ↗ |
|---|---|
| Lead sponsor | Patrick Ott, MD, PhD |
| Collaborators | Bristol-Myers Squibb, Oncovir, Inc. |
| Phase | Phase 1 |
| Status | Active Not Recruiting |
| Indication | Kidney Cancer |
| Enrollment | 19 participants (target) |
| Start date | 2019-03-03 |
| Primary completion | 2027-12-31 (est.) |
| Last registry update | 3 Feb 2026 |
Every field above is mirrored from the study record on ClinicalTrials.gov (NCT02950766), which the sponsor maintains and which carries the full protocol summary, eligibility criteria, sites and contacts. No neoantigen vaccine is approved anywhere yet — every program here is investigational, and inclusion is not an endorsement. See the methodology for how the tracker is built.
Where this fits
Daily coverage of the modality, tumor type and players this study touches:
Related trials
FAQ
What phase is NCT02950766?
NCT02950766 (NeoVax Plus Ipilimumab in Renal Cell Carcinoma) is registered on ClinicalTrials.gov as Phase 1, sponsored by Patrick Ott, MD, PhD.
Is NCT02950766 recruiting?
As of the 2026-02-03 registry update, NCT02950766 is listed as "Active Not Recruiting". Eligibility criteria, study sites and contacts are maintained by the sponsor on the ClinicalTrials.gov record.
Who is running NCT02950766?
The lead sponsor is Patrick Ott, MD, PhD. Collaborators: Bristol-Myers Squibb, Oncovir, Inc..
What condition does NCT02950766 study?
The registered condition is Kidney Cancer. Primary completion is listed as 2027-12-31 (estimated).
Are results available for NCT02950766?
neoag.ai mirrors the registry's factual fields — sponsor, phase, status and dates — and does not publish trial results. Any posted results, publications, or outcome measures appear on the ClinicalTrials.gov record for NCT02950766.
Back to the full neoantigen vaccine trial tracker — 107 studies, refreshed daily from ClinicalTrials.gov. Background: primer, glossary, and the companies landscape.